Cytiva and Pall Investing $1.5 billion to Provide Biotech Solutions

SourceGenetic Engineering and Biotech News
Date Published07/28/2021
Mentions specific company case(s) of reshoring, kept from offshoring, or transplantYes

Additional Reshoring Information:

Company/Division name Cytiva and Pall
Parent companyDanaher
Type of work Manufacturing
Reshoring category:Reshoring
Total number of jobs (added or to be added):250
Year reshoring announced:2021
Domestically, the work will be done:In-house
City reshored to:Logan
State(s) reshored to:UT
If relevant, work nearshored to:-
Product(s) reshoredbiotech products
What non-domestic negative factors made offshoring less attractive?Supply chain interruption risk/Natural disaster risk/Political instability
What domestic positive factors made reshoring more attractive?Customization/Flexibility, Higher productivity, Lead time/Time to market, covid-19
Find Reshoring Articles